艾力斯：目前已有两款产品进入CMC开发阶段

Core Viewpoint - The company has been focusing on the research and development of small molecule innovative drugs while also establishing a large molecule drug discovery team to enhance its R&D capabilities [1] Group 1: Small Molecule Drug Development - The company has a long-standing commitment to the R&D of small molecule innovative drugs [1] - Efforts are being made to consolidate and enhance the existing small molecule drug development foundation [1] Group 2: Large Molecule Drug Development - In recent years, the company has formed a large molecule drug discovery team and built a large molecule R&D platform [1] - The large molecule team is efficiently advancing multiple early-stage projects, with two products already entering the CMC development stage [1] - The company aims to submit IND applications for these products as soon as possible [1]